Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $333.00 Price Target at Wells Fargo & Company

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective hoisted by Wells Fargo & Company from $287.00 to $333.00 in a report issued on Monday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Chardan Capital lifted their target price on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. UBS Group increased their price target on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Finally, Stifel Nicolaus upped their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty have assigned a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $340.00.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $326.09 on Monday. The stock has a 50-day moving average price of $288.10 and a 200 day moving average price of $264.02. The stock has a market capitalization of $42.52 billion, a P/E ratio of -156.02 and a beta of 0.22. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $327.21. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.16) earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the transaction, the chief executive officer owned 48,948 shares in the company, valued at $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. IFP Advisors Inc grew its position in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 47 shares during the last quarter. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $243,000. Silvercrest Asset Management Group LLC purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $1,151,000. Blue Trust Inc. lifted its holdings in Alnylam Pharmaceuticals by 33.9% during the 1st quarter. Blue Trust Inc. now owns 1,158 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 293 shares in the last quarter. Finally, Bridger Management LLC lifted its holdings in Alnylam Pharmaceuticals by 11.2% during the 4th quarter. Bridger Management LLC now owns 41,182 shares of the biopharmaceutical company’s stock valued at $9,691,000 after buying an additional 4,160 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.